Published on January 3, 2013 at 12:59 AM
EPIRUS was financed in early 2011 by 5AM Ventures, Montreux Equity Partners and TPG Biotech. Following a restructuring in 2012, EPIRUS has expanded its focus to centrally develop a broad pipeline of biosimilar monoclonal antibodies, optimised for use within its SCALE™ disposable manufacturing system, and designed to be deployed in an "In Market, For Market" ™ manufacturing configuration. This innovative platform is designed to enable localized manufacturing in key emerging economies where EPIRUS is developing partnerships combining public and private sector financial support and expertise.
EPIRUS President and Chief Executive Officer, Amit Munshi commented, "We are pleased with this initial data and are excited to continue working with our In Market partners globally to continue building out our product pipeline and regional manufacturing model."
SOURCE EPIRUS Biopharmaceuticals, Inc.